March 1, 2023Journal of the American College of Cardiology
Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (Redwood-HCM Cohort 4)
Ahmad MasriMark V. SherridLubna ChoudhuryFlorian RaderChristopher M. KramerSara SaberiTimothy C. WongAslan T. TurerSherif F. NaguehAnjali OwensCaroline CoatsIacopo OlivottoHugh WatkinsMichael A. FiferScott D. SolomonTheodore P. AbrahamSteve HeitnerDan JacobyStuart KupferFady I. MalikLisa MengRegina SohnAmy WohltmanMartin S. Maron
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceAsk about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Currently, there are no evidence-based therapies that are available to help us treat these patients. While we use beta blockers and calcium channel blockers in certain patients, there are no proven therapies that can help these patients feel better or improve the function of the heart.”
“This far exceeds what you expect from placebo.”
“Patients with non-obstructive HCM have no effective medical therapies and lack an apparent therapeutic target like reducing or eliminating the LVOT obstruction, underscoring the need for a therapy to address the underlying cause of the disease. The results from Cohort 4 of REDWOOD-HCM demonstrate that treatment with aficamten is well-tolerated and associated with significant improvements in heart failure symptoms and cardiac biomarkers in patients with non-obstructive HCM and support the advancement of aficamten into a pivotal Phase 3 clinical trial in patients with non-obstructive HCM.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Masri et al. (2023) studied this question.